Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H21ClF2N4O4 |
| Molecular Weight | 466.866 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)C3=CC(Cl)=CC(OC(F)F)=C3)C=C1
InChI
InChIKey=QTUUCFVBSVJGOH-DLBZAZTESA-N
InChI=1S/C21H21ClF2N4O4/c22-14-7-13(8-15(9-14)32-21(23)24)17(29)20(31)28-6-5-16(28)19(30)27-10-11-1-3-12(4-2-11)18(25)26/h1-4,7-9,16-17,21,29H,5-6,10H2,(H3,25,26)(H,27,30)/t16-,17+/m0/s1
| Molecular Formula | C21H21ClF2N4O4 |
| Molecular Weight | 466.866 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Atecegetran metoxil (more widely known as AZD0837), an anticoagulant and a prodrug, converted to a selective and reversible direct thrombin inhibitor (AR-H067637). Atecegetran metoxil participated in phase II clinical trials to prevent the stroke and systemic embolism in patients with non-valvular atrial fibrillation. The development of atecegetran metoxil was discontinued, due to a limitation identified in the long-term stability of the extended-release drug product.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. | 2009 Dec |
|
| Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. | 2009 Jun |
|
| Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. | 2015 Dec |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:37:53 GMT 2023
by
admin
on
Fri Dec 15 20:37:53 GMT 2023
|
| Record UNII |
497U7679T0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
433937-74-7
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY | |||
|
9163
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY | |||
|
917904-13-3
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
300000034114
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY | |||
|
497U7679T0
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY | |||
|
C166740
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY | |||
|
9811290
Created by
admin on Fri Dec 15 20:37:53 GMT 2023 , Edited by admin on Fri Dec 15 20:37:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
